{"id":"https://openalex.org/W2260192576","doi":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","title":"In vivo receptor occupancy of N \u2010desmethylclozapine (ACP\u2010104) and Clozapine","display_name":"In vivo receptor occupancy of N \u2010desmethylclozapine (ACP\u2010104) and Clozapine","publication_year":2008,"publication_date":"2008-03-01","ids":{"openalex":"https://openalex.org/W2260192576","doi":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","mag":"2260192576"},"language":"en","primary_location":{"id":"doi:10.1096/fasebj.22.1_supplement.1127.8","doi":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049273438","display_name":"Pey\u2010Lih H Littler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pey\u2010Lih H Littler","raw_affiliation_strings":["Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054124191","display_name":"Kara R. Schmelzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kara R Schmelzer","raw_affiliation_strings":["Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012594959","display_name":"Krista McFarland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Krista McFarland","raw_affiliation_strings":["Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070529034","display_name":"Douglas W. Bonhaus","orcid":"https://orcid.org/0000-0002-6567-2348","observed_orcids":["https://orcid.org/0000-0002-6567-2348"]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas W Bonhaus","raw_affiliation_strings":["Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005645056","display_name":"Jelveh Lameh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jelveh Lameh","raw_affiliation_strings":["Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences, ACADIA Pharmaceuticals, Inc., San Diego, CA","institution_ids":["https://openalex.org/I125377440"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I125377440"],"apc_list":{"value":3740,"currency":"USD","value_usd":3740},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.32287761,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"S1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9150000214576721,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9150000214576721,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.06210000067949295,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.006599999964237213,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/n-desmethylclozapine","display_name":"N-desmethylclozapine","score":0.9800000190734863},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.8569999933242798},{"id":"https://openalex.org/keywords/receptor-occupancy","display_name":"receptor occupancy","score":0.9240000247955322},{"id":"https://openalex.org/keywords/5-ht2a-receptor","display_name":"5-HT2A receptor","score":0.8790000081062317},{"id":"https://openalex.org/keywords/muscarinic-m1-receptor","display_name":"M1 muscarinic receptor","score":0.996999979019165},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.9049999713897705},{"id":"https://openalex.org/keywords/antipsychotic-activity","display_name":"antipsychotic activity","score":0.7310000061988831},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.878000020980835},{"id":"https://openalex.org/keywords/prefrontal-cortex","display_name":"prefrontal cortex","score":0.8410000205039978},{"id":"https://openalex.org/keywords/clozapine-metabolites","display_name":"clozapine metabolites","score":0.8399999737739563}],"concepts":[{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.8556491136550903},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7282925844192505},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.6491358280181885},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5575025081634521},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5561020374298096},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5424414873123169},{"id":"https://openalex.org/C53910766","wikidata":"https://www.wikidata.org/wiki/Q238516","display_name":"5-HT receptor","level":4,"score":0.46263593435287476},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.44798073172569275},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.4384111166000366},{"id":"https://openalex.org/C2910202354","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic Agent","level":4,"score":0.4338299036026001},{"id":"https://openalex.org/C2775870346","wikidata":"https://www.wikidata.org/wiki/Q2554162","display_name":"Typical antipsychotic","level":5,"score":0.41742733120918274},{"id":"https://openalex.org/C200220013","wikidata":"https://www.wikidata.org/wiki/Q753586","display_name":"5-HT2 receptor","level":5,"score":0.4145227074623108},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.39691755175590515},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38467758893966675},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.29723984003067017},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.252291202545166},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2056172490119934},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.09155270457267761},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1096/fasebj.22.1_supplement.1127.8","doi":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.22.1_supplement.1127.8","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W12041443","https://openalex.org/W2062009247","https://openalex.org/W1989299632","https://openalex.org/W2046479063","https://openalex.org/W2016278859","https://openalex.org/W2003621314","https://openalex.org/W2021637704","https://openalex.org/W2011180752","https://openalex.org/W2996338950","https://openalex.org/W2327913641"],"abstract_inverted_index":{"Acadia":[0],"is":[1,40,62],"currently":[2],"developing":[3],"ACP\u2010104":[4,61,78,136,145,161,190],"(":[5],"N":[6],"\u2010desmethylclozapine,":[7],"NDMC)":[8],"as":[9,191],"an":[10,41,63],"antipsychotic":[11,81,178,194],"with":[12,163],"potential":[13,187],"procognitive":[14,83,180,193],"benefits.":[15],"A":[16],"number":[17],"of":[18,23,31,98,189,199],"clinical":[19],"and":[20,51,67,82,100,108,124,135,146,166,179],"preclinical":[21],"lines":[22],"evidence":[24],"suggest":[25],"that":[26,60,77,133,160,174],"NDMC,":[27],"a":[28,192],"predominant":[29],"metabolite":[30],"clozapine,":[32],"may":[33],"contribute":[34],"to":[35,91,105,138,149],"clozapine's":[36],"superior":[37],"efficacy.":[38],"Clozapine":[39],"antagonist":[42],"at":[43,172],"serotonin":[44],"5\u2010HT":[45,106,140,164],"2A":[46,107,141,165],",":[47],"muscarinic":[48],"M":[49,64,109,150,167],"1,":[50],"dopamine":[52],"D":[53,68],"2":[54,69],"receptors,":[55],"while":[56],"we":[57],"have":[58,75],"shown":[59,76],"1":[65,110,151,168],"agonist":[66],"partial":[70],"agonist.":[71],"In":[72,102],"vivo":[73,88,95,103,171],"studies":[74],"has":[79],"both":[80,144],"activity.":[84],"We":[85],"utilized":[86],"ex":[87],"binding":[89,104],"assays":[90],"study":[92],"the":[93,154,186,197],"in":[94,114,153,170,177,196],"receptor":[96],"occupancy":[97],"clozapine":[99,134,147],"ACP\u2010104.":[101],"receptors":[111,152,169],"was":[112],"assessed":[113],"rat":[115],"pre\u2010frontal":[116],"cortex":[117],"by":[118],"[":[119,125],"3":[120,126],"H]":[121,127],"MDL100,":[122],"907":[123],"pirenzepine,":[128],"respectively.":[129],"Our":[130,183],"data":[131,158],"show":[132],"bind":[137,148],"cortical":[139],"receptors.":[142],"Moreover,":[143],"prefrontal":[155],"cortex.":[156],"These":[157],"demonstrate":[159],"interacts":[162],"doses":[173],"are":[175],"effective":[176],"animal":[181],"models.":[182],"findings":[184],"support":[185],"utility":[188],"agent":[195],"treatment":[198],"schizophrenia.":[200]},"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}